טוען...
Evaluating assumptions of definition-based pulmonary exacerbation endpoints in cystic fibrosis clinical trials
BACKGROUND: Cystic fibrosis (CF) pulmonary exacerbations can be serious respiratory events and reduction in exacerbation rate or risk are important efficacy endpoints for CF therapeutic trials. Variability in exacerbation diagnoses and treatment have led drug developers to employ “objective” exacerb...
שמור ב:
| הוצא לאור ב: | J Cyst Fibros |
|---|---|
| Main Authors: | , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
European Cystic Fibrosis Society. Published by Elsevier B.V.
2021
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7362840/ https://ncbi.nlm.nih.gov/pubmed/32682670 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jcf.2020.07.008 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|